Search

• 

  Codes, standards and reports

  Company

  Find out about our codes, standards and reports

  https://www.gsk.com/en-gb/company/codes-standards-and-reports/

  First published: 19 November 2024

• GSK and Theravance announce start of phase III lung function study with ‘closed’ triple combination treatment FF/UMEC/VI for COPD

  Media

  GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the start of a second global phase III study

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-start-of-phase-iii-lung-function-study-with-closed-triple-combination-treatment-ffumecvi-for-copd/

  First published: 09 February 2015

• GSK to divest ofatumumab for auto-immune indications to Novartis for up to $1 billion plus royalties

  Media

  GSK announced an agreement with Novartis Pharma to divest its rights in ofatumumab for auto-immune indications, incl. multiple sclerosis.

  https://www.gsk.com/en-gb/media/press-releases/gsk-to-divest-ofatumumab-for-auto-immune-indications-to-novartis-for-up-to-1-billion-plus-royalties/

  First published: 21 August 2015

• GSK announces NEJM publication of Phase 3b/4 study of ambrisentan and tadalafil as first-line combination treatment in patients with pulmonary arterial hypertension

  Media

  GSK today announced publication of first-line combination therapy of ambrisentan and tadalafil in treatment-naïve patients with PAH.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-nejm-publication-of-phase-3b4-study-of-ambrisentan-and-tadalafil-as-first-line-combination-treatment-in-patients-with-pulmonary-arterial-hypertension/

  First published: 26 August 2015

• Comic Relief and GSK form five-year partnership to fight malaria and strengthen health systems

  Media

  A five-year partnership to fight malaria and improve health in five countries has today been launched by Comic Relief and GSK.

  https://www.gsk.com/en-gb/media/press-releases/comic-relief-and-gsk-form-five-year-partnership-to-fight-malaria-and-strengthen-health-systems/

  First published: 15 December 2015

• GSK completes divestment of rights to ofatumumab for auto-immune indications to Novartis

  Media

  GSK announced completion of its divesting of rights to ofatumumab for auto-immune indications to Novartis Pharma following reg. approval.

  https://www.gsk.com/en-gb/media/press-releases/gsk-completes-divestment-of-rights-to-ofatumumab-for-auto-immune-indications-to-novartis/

  First published: 21 December 2015

• GSK announces headline results for Phase III study of the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib) in metastatic melanoma

  Media

  GSK announced that a Phase III study of the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib) met its primary endpoint of PFS

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-headline-results-for-phase-iii-study-of-the-combination-of-tafinlar-dabrafenib-and-mekinist-trametinib-in-metastatic-melanoma/

  First published: 24 January 2014

• GSK announces new strategic investments in Africa to increase access to medicines, build capacity and deliver sustainable growth

  Media

  GSK today announced a series of investments in sub-Saharan Africa designed to address pressing needs and contribute to long-term growth.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-new-strategic-investments-in-africa-to-increase-access-to-medicines-build-capacity-and-deliver-sustainable-growth/

  First published: 31 March 2014

• GlaxoSmithKline reaches agreement with Aspen to divest thrombosis brands and related manufacturing site for £0.7 billion

  Media

  Divestment supports strategic focus and delivery of pipeline.

  https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-reaches-agreement-with-aspen-to-divest-thrombosis-brands-and-related-manufacturing-site-for-07-billion/

  First published: 30 September 2013

• GSK announces US regulatory submission for fluticasone furoate monotherapy for asthma

  Media

  GSK announced the submission of a New Drug Application in the US for ICS treatment, FF administered using the ELLIPTA™ dry powder inhaler.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-us-regulatory-submission-for-fluticasone-furoate-monotherapy-for-asthma/

  First published: 23 October 2013